Protagonist Therapeutics, Inc Contracts & Agreements

62 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
License and Collaboration Agreement by and between Protagonist Therapeutics, Inc. and Takeda Pharmaceuticals USA, Inc. dated January 31, 2024
Collaboration Agreements
Protagonist Therapeutics, Inc
2024
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
Protagonist Therapeutics, Inc
2024
Form of Pre-Funded Warrant
Warrant Agreements
Protagonist Therapeutics, Inc
2023
Underwriting Agreement, dated April 4, 2023
Underwriting Agreements
Protagonist Therapeutics, Inc
Biotechnology
NY
2023
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
Protagonist Therapeutics, Inc
2023
Offer Letter, by and between Protagonist Therapeutics Inc. and Arturo Molina, M.D., Ph.D., dated November 1, 2022
Protagonist Therapeutics, Inc
Biotechnology
2023
Severance Agreement, by and between Protagonist Therapeutics Inc. and Arturo Molina, M.D., Ph.D., dated November 7, 2022
Severance Agreements
Protagonist Therapeutics, Inc
2023
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
Protagonist Therapeutics, Inc
2022
Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc
Collaboration Agreements
Protagonist Therapeutics, Inc
Biotechnology
NY
2021
Arbitration Resolution Agreement, dated August 4th, 2021, by and among Protagonist Therapeutics, Inc. and Zealand Pharma, A/S
Protagonist Therapeutics, Inc
2021
Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord
Lease Agreements
Protagonist Therapeutics, Inc
2021
Underwriting Agreement, dated June 15, 2021
Underwriting Agreements
Protagonist Therapeutics, Inc
2021
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
Protagonist Therapeutics, Inc
2021
Underwriting Agreement, dated December 10, 2020
Underwriting Agreements
Protagonist Therapeutics, Inc
Biotechnology
NY
2020
Severance Agreement, dated August 4, 2020, by and between Protagonist Therapeutics, Inc. and Don Kalkofen
Severance Agreements
Protagonist Therapeutics, Inc
Biotechnology
CA
2020
Underwriting Agreement, dated as of May 11, 2020
Underwriting Agreements
Protagonist Therapeutics, Inc
2020
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
Protagonist Therapeutics, Inc
2020
Protagonist Therapeutics, Inc. Amended and Restated 2018 Inducement Plan
Protagonist Therapeutics, Inc
Biotechnology
DE
2020
Open Market Sale AgreementSM, dated November 27, 2019, by and between Protagonist Therapeutics, Inc. and Jefferies LLC
Protagonist Therapeutics, Inc
Biotechnology
NY
2019
Severance Agreement, dated July 19, 2019, by and between Protagonist Therapeutics, Inc. and Samuel Saks, M.D
Severance Agreements
Protagonist Therapeutics, Inc
2019
First Amendment to Exclusive License and Collaboration Agreement, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., dated May 7, 2019
Collaboration Agreements
Protagonist Therapeutics, Inc
Biotechnology
2019
Offer Letter between Protagonist Therapeutics, Inc. and Donald Kalkofen, dated May 20, 2019
Protagonist Therapeutics, Inc
2019
Separation Agreement between Protagonist Therapeutics, Inc. and Richard S. Shames, dated May 7, 2019
Separation Agreements
Protagonist Therapeutics, Inc
2019
First Amendment, dated January 31, 2019, to Lease, dated March 6, 2017, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center LP
Lease Agreements
Protagonist Therapeutics, Inc
Biotechnology
2019
Severance Agreement, dated March 14, 2019, by and among Protagonist Therapeutics, Inc. and Suneel Gupta, Ph.D
Severance Agreements
Protagonist Therapeutics, Inc
Biotechnology
CA
2019
Form of Warrant
Warrant Agreements
Protagonist Therapeutics, Inc
Biotechnology
NY
2018
Exchange Agreement between Protagonist Therapeutics, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P.,...
Exchange Agreements
Protagonist Therapeutics, Inc
Biotechnology
2018
Employment Offer Letter by and between the Company and Samuel Saks, M.D. dated as of May 21, 2018
Employment Agreements
Protagonist Therapeutics, Inc
2018
Form of Class A Common Stock Purchase Warrant
Warrant Agreements
Protagonist Therapeutics, Inc
2018
Form of Class B Common Stock Purchase Warrant
Warrant Agreements
Protagonist Therapeutics, Inc
2018
Form of Registration Rights Agreement
Registration Rights Agreements
Protagonist Therapeutics, Inc
Biotechnology
DE
2018
Underwriting Agreement, dated as of October 11, 2017, by and among Protagonist Therapeutics, Inc., Leerink Partners LLC and Barclays Capital Inc
Underwriting Agreements
Protagonist Therapeutics, Inc
Biotechnology
DE
2017
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN JANSSEN BIOTECH, INC. AND PROTAGONIST THERAPEUTICS, INC.
Collaboration Agreements
Protagonist Therapeutics, Inc
2017
LEASE by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership and PROTAGONIST THERAPEUTICS,INC., a Delaware corporation Table of Contents
Lease Agreements
Protagonist Therapeutics, Inc
Biotechnology
CA
2017
FOURTH AMENDMENT TO LEASE
Lease Agreements
Protagonist Therapeutics, Inc
2016
DATED 16 JUNE 2012 (1) ZEALAND PHARMA A/S (2) PROTAGONIST PTY. LTD. (3) PROTAGONIST THERAPEUTICS, INC. RESEARCHCOLLABORATION AND LICENSE AGREEMENT ZEALAND PHARMA/PROTAGONIST...
Collaboration Agreements
Protagonist Therapeutics, Inc
2016
CONTRACTEXTENSION LETTER OF AGREEMENT hereinafter (Contract Extension) made effective as of June 1st 2013 (Contract Extension Effective Date).
Protagonist Therapeutics, Inc
Biotechnology
2016
Agreement onaddition of Additional Collaboration Program hereinafter (AACP) made effective as of September 16th 2013 (AACP Effective Date).
Collaboration Agreements
Protagonist Therapeutics, Inc
Biotechnology
2016
AGREEMENT TOASSIGN PATENT APPLICATIONS
Protagonist Therapeutics, Inc
2016
ABANDONMENTAGREEMENT
Protagonist Therapeutics, Inc
2016
PROTAGONIST THERAPEUTICS, INC. (a Delaware corporation) [] Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreements
Protagonist Therapeutics, Inc
Biotechnology
DE
2016
Additional abbreviations may also be used though not in the above list.
Protagonist Therapeutics, Inc
2016
PROTAGONIST THERAPEUTICS, INC. THIRD AMENDEDAND RESTATED INVESTOR RIGHTS AGREEMENT July 31, 2016 PROTAGONIST THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS...
Investor Rights Agreements
Protagonist Therapeutics, Inc
2016
PROTAGONIST THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JULY 28, 2016 APPROVED BY THE STOCKHOLDERS:JULY 31, 2016 EFFECTIVE DATE: JULY 28, 2016
Bonus & Incentive Agreements
Protagonist Therapeutics, Inc
Biotechnology
DE
2016
PROTAGONIST THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JULY 28, 2016 APPROVED BY THE STOCKHOLDERS:JULY 31, 2016
Stock Agreements
Protagonist Therapeutics, Inc
2016
INDEMNITY AGREEMENT
Protagonist Therapeutics, Inc
Biotechnology
DE
2016
EMPLOYEE SEVERANCE AGREEMENT
Severance Agreements
Protagonist Therapeutics, Inc
Biotechnology
CA
2016
EMPLOYEE SEVERANCE AGREEMENT
Severance Agreements
Protagonist Therapeutics, Inc
2016
EMPLOYEE SEVERANCE AGREEMENT
Severance Agreements
Protagonist Therapeutics, Inc
2016
EMPLOYEE SEVERANCE AGREEMENT
Severance Agreements
Protagonist Therapeutics, Inc
2016
EMPLOYEE SEVERANCE AGREEMENT
Severance Agreements
Protagonist Therapeutics, Inc
Biotechnology
CA
2016
PROTAGONIST THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORRIGHTS AGREEMENT July 10, 2015 PROTAGONIST THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS...
Investor Rights Agreements
Protagonist Therapeutics, Inc
2016
PROTAGONIST THERAPEUTICS, INC. 2007 STOCK OPTION AND INCENTIVE PLAN (AS AMENDED AND RESTATED)
Bonus & Incentive Agreements
Protagonist Therapeutics, Inc
2016
LEASE
Lease Agreements
Protagonist Therapeutics, Inc
2016
FIRST AMENDMENT TO LEASE
Lease Agreements
Protagonist Therapeutics, Inc
2016
SECOND AMENDMENT TO LEASE
Lease Agreements
Protagonist Therapeutics, Inc
Biotechnology
2016
THIRD AMENDMENT TO LEASE
Lease Agreements
Protagonist Therapeutics, Inc
Biotechnology
2016
DATED 16 JUNE 2012 (1) ZEALAND PHARMA A/S (2) PROTAGONIST PTY. LTD. (3) PROTAGONIST THERAPEUTICS, INC. RESEARCHCOLLABORATION AND LICENSE AGREEMENT
License Agreements
Protagonist Therapeutics, Inc
2016
CONTRACTEXTENSION LETTER OF AGREEMENT hereinafter (Contract Extension) made effective as of June 1st 2013 (Contract Extension Effective Date).
Protagonist Therapeutics, Inc
2016
Agreement onaddition of Additional Collaboration Program hereinafter (AACP) made effective as of September 16th 2013 (AACP Effective Date).
Collaboration Agreements
Protagonist Therapeutics, Inc
Biotechnology
2016
AGREEMENT TOASSIGN PATENT APPLICATIONS
Protagonist Therapeutics, Inc
2016
ABANDONMENTAGREEMENT
Protagonist Therapeutics, Inc
2016